Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Ann Surg. 2018 Jan;267(1):157–163. doi: 10.1097/SLA.0000000000002015

TABLE 1.

Patient characteristics from training population and univariate analysis (n = 662). Patients with a history of jaundice (n = 58) were excluded from training set. Median (low–high) or N (%).

Training set (n = 662)
Main duct and mixed-type (n = 281) Branch duct (n = 381)
Total
(n)		 High-risk
(n = 191)		 Low-risk
(n = 90)		 P-value Total
(n)		 High-risk
(n = 105)		 Low-risk
(n = 276)		 P-value
Institution
 MSK 99
(35%)		 71
(37%)		 28
(31%)		 0.331 129
(34%)		 40
(38%)		 89
(32%)		 0.569
 JHH 93
(33%)		 65
(34%)		 28
(31%)		 152
(40%)		 39
(37%)		 113
(41%)
 MGH 89
(32%)		 55
(29%)		 34
(38%)		 100
(26%)		 26
(25%)		 74
(27%)
Age 68
(18–92)		 67
(18–92)		 69
(30–89)		 0.244 67
(34–92)		 70
(41–92)		 66
(34–88)		 0.011a
Body Mass Index 25.8
(15.5–46.1)		 25.9
(15.5–46.1)		 25.4
(17.5–38.1)		 0.922 26.0
(15.0–47.0)		 25.7
(17.6–47.0)		 26.3
(15.0–43.2)		 0.383
Gender
 Male 154
(55%)		 112
(59%)		 42
(47%)		 0.072 160
(42%)		 50
(48%)		 110
(40%)		 0.201a
 Female 127
(45%)		 79
(41%)		 48
(53%)		 221
(58%)		 55
(52%)		 166
(60%)
Diabetes
 Yes 78
(28%)		 56
(29%)		 22
(24%)		 0.476 58
(15%)		 15
(14%)		 43
(16%)		 0.873
 No 203
(72%)		 135
(71%)		 68
(76%)		 323
(85%)		 90
(86%)		 233
(84%)
Pancreatitis
 Yes 91
(32%)		 62
(32%)		 29
(32%)		 1.000 81
(21%)		 25
(24%)		 56
(20%)		 0.484
 No 190
(68%)		 129
(68%)		 61
(68%)		 300
(79%)		 80
(76%)		 220
(80%)
Personal history of cancer
 Yes 64
(23%)		 39
(20%)		 25
(28%)		 0.174 68
(18%)		 20
(19%)		 48
(17%)		 0.765
 No 217
(77%)		 152
(80%)		 65
(72%)		 313
(82%)		 85
(81%)		 228
(83%)
Family history of pancreatic cancer
 Yes 31
(11%)		 20
(10%)		 11
(12%)		 0.686 64
(17%)		 7
(7%)		 57
(21%)		 <0.001
 No 250
(89%)		 171
(90%)		 79
(88%)		 317
(83%)		 98
(93%)		 219
(79%)
Symptomatic
 Yes 159
(57%)		 117
(61%)		 42
(47%)		 0.028a 167
(44%)		 53
(50%)		 114
(41%)		 0.133a
 No 122
(43%)		 74
(39%)		 48
(53%)		 214
(56%)		 52
(50%)		 162
(59%)
Weight loss
 Yes 93
(33%)		 73
(38%)		 20
(22%)		 0.010a 51
(13%)		 16
(15%)		 35
(13%)		 0.505
 No 188
(67%)		 118
(62%)		 70
(78%)		 330
(87%)		 89
(85%)		 241
(87%)
CA 19-9 (serum) > 40b
 Yes 42
(23%)		 36
(29%)		 6
(10%)		 0.003 35
(16%)		 16
(28%)		 19
(12%)		 0.007
 No 141
(77%)		 86
(71%)		 55
(90%)		 185
(84%)		 42
(72%)		 143
(88%)
Solid component/ mural nodulec
 Yes 122
(43%)		 94
(49%)		 28
(31%)		 0.005a 102
(27%)		 41
(39%)		 61
(22%)		 0.001a
 No 159
(57%)		 97
(51%)		 62
(69%)		 279
(73%)		 64
(61%)		 215
(78%)
Number of cysts
 0 52
(19%)		 42
(22%)		 10
(11%)		 0.001a N/A N/A N/A 0.381
 1 158
(56%)		 110
(58%)		 48
(53%)		 223
(60%)		 69
(66%)		 154
(58%)
 2 29
(10%)		 21
(11%)		 8
(9%)		 53
(14%)		 14
(13%)		 39
(15%)
 3 + 42
(15%)		 18
(9%)		 24
(27%)		 94
(26%)		 22
(21%)		 72
(27%)
Largest cyst sized
 ≤ 3.0 cm 113
(42%)		 63
(34%)		 50
(58%)		 <0.001a 253
(67%)		 54
(52%)		 199
(72%)		 <0.001a
 > 3.0 cm 106
(39%)		 80
(43%)		 26
(30%)		 127
(33%)		 50
(48%)		 77
(28%)
 None seen 52
(19%)		 42
(23%)		 10
(12%)		 N/A N/A N/A
MPD size
 0.5 cm < and ≤1.0 cm 220
(78%)		 144
(75%)		 76
(84%)		 0.091a N/A N/A N/A N/A
 > 1.0 cm 61
(22%)		 47
(25%)		 14
(16%)		 N/A N/A N/A
a

Variables used in subsequent multivariate analysis

b

Preoperative CA 19-9 was only available for 183/281 (65%) MD-IPMN and 220/381 (58%) BD-IPMN patients

c

Solid component, thickened or enhanced cyst, mural nodule, or concurrent lesion

d

Ten MD-IPMN patients and one BD-IPMN patient did not have cyst size information available.

MSK=Memorial Sloan Kettering, JHH=Johns Hopkins, MGH=Massachusetts General Hospital

MPD=Main pancreatic duct

IQR=Interquartile range